All In Biotech

Drug Trial Radar · NCT07089121

Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

Descartes-08 for Children, Adolescents and Young Adults With Childhood-onset Systemic Lupus Erythematosus, ANCA-associated Vasculitis, Juvenile Myasthenia Gravis, and Juvenile Dermatomyositis

Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Jan 14, 2026

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Cartesian TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis

Conditions

  • Childhood-onset Systemic Lupus Erythematous
  • ANCA-Associated Vasculitis (AAV)
  • Juvenile Myasthenia Gravis
  • Juvenile Dermatomyositis

Interventions

  • Descartes-08Drug

    In part 1, three different doses will be administered to 3 participants with either disease indication to establish maximum tolerated dose In part 2, the MTD established in Part-1 will be administered as six once-weekly infusions to up to 10 participants per each of four baskets (cSLE, AAV, JDM and JMG) in an outpatient setting.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose in Part 1, type and frequency of treatment related SAE's in Part 2Time frame: Days 22 and 50 for Part1 , Days 22, 50 and Months 3,6,9 and 12 for part 2
  2. Maximum Dose ToleratedTime frame: Days 2250 for Part 1, Days 11,50, month 3 for part 2 in addition to months, 4,6,9,12

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • H01- Children's National Hospital

    Washington D.C., District of Columbia · Recruiting

  • H03- Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.